Barclays PLC Has $123,000 Stake in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Barclays PLC increased its stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 323.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,560 shares of the company’s stock after purchasing an additional 6,538 shares during the quarter. Barclays PLC owned approximately 0.07% of Greenwich LifeSciences worth $123,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences in the 2nd quarter worth approximately $117,000. Bank of New York Mellon Corp acquired a new position in shares of Greenwich LifeSciences in the second quarter worth $264,000. Garden State Investment Advisory Services LLC purchased a new stake in shares of Greenwich LifeSciences during the third quarter worth $253,000. State Street Corp boosted its position in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after purchasing an additional 5,861 shares in the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock in a transaction that occurred on Friday, January 10th. The stock was acquired at an average price of $12.51 per share, with a total value of $31,275.00. Following the purchase, the chief executive officer now owns 5,552,502 shares in the company, valued at approximately $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders bought 10,500 shares of company stock valued at $128,459. 51.67% of the stock is owned by corporate insiders.

Greenwich LifeSciences Price Performance

Shares of GLSI stock opened at $13.00 on Friday. Greenwich LifeSciences, Inc. has a fifty-two week low of $8.00 and a fifty-two week high of $21.44. The stock’s 50-day moving average is $12.92 and its two-hundred day moving average is $13.85. The firm has a market cap of $170.95 million, a P/E ratio of -16.25 and a beta of 1.66.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.